Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Kelun-Biotech (科伦博泰) IPO: Fairly Valued at Best

Kelun-Biotech (科伦博泰) IPO Trading: Lukewarm Demand but Peers Have Done Well Recently

Kelun-Biotech IPO Lock-Up Expiry - Strong Performance Leaves Pre-IPO Investors with Large Gains

Kelun-Biotech (科伦博泰) Pre-IPO: Candidates Are Differentiated and Promising

RemeGen (荣昌生物) Pre-IPO: Top-Notch R&D Capability and a Strong Team

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Kelun-Biotech, a China-based integrated innovative biopharmaceutical company, plans to raise up to US$400m via a Hong Kong listing.</li>
<li>In our previous note, we examined the company's two core products, namely SKB264, a TROP2-ADC, and A166, a HER2-ADC.</li>
<li>In this note, we will provide a valuation for the company's key products.</li>
</ul>


Kelun-Biotech, a China-based integrated innovative biopharmaceutical company, plans to raise up to US$400m via a Hong Kong listing.
In our previous note, we examined the company's two core products, namely SKB264, a TROP2-ADC, and A166, a HER2-ADC.
In this note, we will provide a valuation for the company's key products.


Kelun-Biotech (科伦博泰) Pre-IPO: Thoughts on Valuation

Kelun Biotech

Kelun-Biotech (科伦博泰) Pre-IPO: Thoughts on Valuation